1. Home
  2. RDHL vs LICN Comparison

RDHL vs LICN Comparison

Compare RDHL & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • LICN
  • Stock Information
  • Founded
  • RDHL 2009
  • LICN 2004
  • Country
  • RDHL Israel
  • LICN China
  • Employees
  • RDHL N/A
  • LICN N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • LICN
  • Sector
  • RDHL Health Care
  • LICN
  • Exchange
  • RDHL Nasdaq
  • LICN Nasdaq
  • Market Cap
  • RDHL 3.9M
  • LICN 3.8M
  • IPO Year
  • RDHL N/A
  • LICN 2023
  • Fundamental
  • Price
  • RDHL $1.70
  • LICN $4.66
  • Analyst Decision
  • RDHL
  • LICN
  • Analyst Count
  • RDHL 0
  • LICN 0
  • Target Price
  • RDHL N/A
  • LICN N/A
  • AVG Volume (30 Days)
  • RDHL 43.1K
  • LICN 84.7K
  • Earning Date
  • RDHL 09-05-2025
  • LICN 01-01-0001
  • Dividend Yield
  • RDHL N/A
  • LICN N/A
  • EPS Growth
  • RDHL N/A
  • LICN N/A
  • EPS
  • RDHL N/A
  • LICN N/A
  • Revenue
  • RDHL $9,550,000.00
  • LICN $41,477,000.00
  • Revenue This Year
  • RDHL $381.91
  • LICN N/A
  • Revenue Next Year
  • RDHL N/A
  • LICN N/A
  • P/E Ratio
  • RDHL N/A
  • LICN N/A
  • Revenue Growth
  • RDHL 157.62
  • LICN 4.32
  • 52 Week Low
  • RDHL $1.06
  • LICN $2.60
  • 52 Week High
  • RDHL $11.70
  • LICN $462.00
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 63.39
  • LICN 49.94
  • Support Level
  • RDHL $1.47
  • LICN $4.59
  • Resistance Level
  • RDHL $1.60
  • LICN $5.30
  • Average True Range (ATR)
  • RDHL 0.09
  • LICN 0.48
  • MACD
  • RDHL 0.04
  • LICN -0.01
  • Stochastic Oscillator
  • RDHL 97.98
  • LICN 31.25

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: